5-Amino-1MQ: Mechanism, Benefits, and How It Works
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule selective inhibitor of nicotinamide N-methyltransferase (NNMT) that increases intracellular NAD+ and SAM availability in adipocytes and muscle cells. It is a research compound studied for fat loss, metabolic flexibility, and muscle preservation, and is currently used investigationally rather than as an approved therapeutic.
5-Amino-1MQ belongs to a class of small molecules designed to selectively block nicotinamide N-methyltransferase (NNMT), an enzyme that becomes overexpressed in fat tissue with aging, obesity, and metabolic dysfunction. By inhibiting NNMT, 5-Amino-1MQ aims to spare NAD+ and SAM — two cofactors central to energy metabolism and methylation. Originally developed as a research tool to validate NNMT as a drug target, it has gained interest in longevity and body-composition circles as a potential metabolic optimizer, though it remains a preclinical/investigational compound.
Key Takeaways
- 5-Amino-1MQ is a selective small-molecule inhibitor of the enzyme NNMT.
- By blocking NNMT, it preserves nicotinamide for NAD+ synthesis and SAM for methylation.
- NNMT is elevated in obesity, aging, and metabolic dysfunction, making it a logical drug target.
- Preclinical animal studies show reductions in adiposity and improved metabolic markers without changes in food intake.
- Human clinical trial data are currently limited; the compound is investigational.
- It is not stimulant-like and works gradually over weeks of consistent dosing.
- Use should be guided by a qualified clinician and sourced from quality-controlled suppliers.
- DrSeinfeld does not currently carry 5-Amino-1MQ; related metabolic and NAD+ tools are available in our catalog.
How It Works (Mechanism of Action)
5-Amino-1MQ works by selectively inhibiting nicotinamide N-methyltransferase (NNMT), an enzyme that catalyzes the methylation of nicotinamide (NAM) using S-adenosylmethionine (SAM) as a methyl donor, producing 1-methylnicotinamide (1-MNA) and S-adenosylhomocysteine (SAH). NNMT is highly expressed in white adipose tissue, liver, and skeletal muscle, and its expression is elevated in obesity, type 2 diabetes, certain cancers, and with aging. When NNMT activity is high, it acts as a metabolic 'sink,' depleting nicotinamide (a key NAD+ precursor) and SAM (the universal methyl donor), and simultaneously promoting a futile cycle that consumes ATP through accelerated polyamine flux. By blocking NNMT, 5-Amino-1MQ allows nicotinamide to remain available for NAD+ salvage, preserves SAM for methylation reactions (including histone and DNA methylation that regulate metabolic gene expression), and reduces the wasteful ATP drain in adipocytes. Preclinical studies have shown that NNMT inhibition increases intracellular NAD+ and SAM in adipose tissue, enhances cellular energy expenditure, reduces lipogenesis, and shifts adipocytes toward a more metabolically active phenotype. In skeletal muscle, NNMT inhibition has been linked to improved stem-cell function and muscle regeneration in aged animal models, likely through restored NAD+ and improved methylation status. Importantly, 5-Amino-1MQ is selective for NNMT over related methyltransferases, and unlike systemic NAD+ precursors, it raises NAD+ specifically in tissues where NNMT is elevated rather than broadly.
What the Research Shows
Research on 5-Amino-1MQ is largely preclinical. Animal and cell studies — primarily in diet-induced obese mice — suggest that NNMT inhibition with 5-Amino-1MQ can reduce body weight and white adipose tissue mass without affecting food intake, improve insulin sensitivity markers, and increase cellular NAD+ and SAM in target tissues. Additional rodent work has explored its role in muscle stem cell function, with preliminary evidence indicating improved regeneration in aged muscle. Cancer biology research has examined NNMT inhibitors more broadly because NNMT overexpression appears in several tumor types, though 5-Amino-1MQ itself is not a clinical oncology agent. To date, there are no published large-scale human clinical trials of 5-Amino-1MQ, and no regulatory approval exists for any indication. Human pharmacokinetics, optimal dosing, long-term safety, and translation of animal metabolic effects to humans remain open questions. Anecdotal use in wellness and body-composition contexts has outpaced the formal evidence base, so claims about fat loss, muscle preservation, and longevity should be considered hypothesis-generating rather than clinically proven. Anyone considering 5-Amino-1MQ should view it as an investigational compound and discuss it with a qualified clinician.
Delivery Format Comparison
| Format | Bioavailability | Onset | Duration | Best For |
|---|---|---|---|---|
| Oral | Moderate; preclinical models show systemic exposure with oral dosing | Pharmacologic effects build over days to weeks of consistent dosing | Effects on tissue NAD+/SAM persist with daily dosing; washout over days off | Adults exploring NNMT inhibition for metabolic support who want a simple daily protocol. |
| Sublingual | Theoretically higher than oral by bypassing first-pass; not formally characterized for this molecule | Minutes for absorption; pharmacodynamic effects still cumulative | Similar to oral once steady state is reached | Users seeking alternative absorption when oral tolerability is an issue. |
| Subcutaneous injection | High systemic exposure | Rapid absorption from injection site | Comparable to other parenteral small molecules | Clinical research settings where precise plasma levels are required. |
| Topical | Localized; minimal systemic absorption | Local skin-level effects only | Depends on application frequency | Experimental localized use; not a substitute for systemic dosing in research models. |
Dosing Approach
Because 5-Amino-1MQ is an investigational compound without an approved human label, no medically validated dose exists. Animal studies have used weight-scaled oral dosing, and human extrapolations are speculative. In practical wellness use, protocols typically center on once-daily oral administration taken in the morning, often cycled (for example, several weeks on followed by a break) to allow assessment of response and tolerability. Factors that thoughtful users and clinicians weigh include body weight, baseline metabolic health, concurrent use of NAD+ precursors or methyl donors, and overall medication burden. Because NNMT inhibition affects methylation cofactor balance, some practitioners pay attention to methylation status (B12, folate, methylation-related symptoms) when considering longer cycles. 5-Amino-1MQ is not a stimulant and is not expected to produce acute felt effects; outcomes are evaluated over weeks. DrSeinfeld does not manufacture or sell 5-Amino-1MQ and does not provide dosing recommendations. Anyone considering this compound should work with a qualified medical provider, source from a reputable pharmacy or laboratory with third-party testing, and avoid combining multiple novel compounds without oversight.
Important: Specific dosing should always be guided by the product label and a qualified healthcare provider familiar with your medical history.
Safety Profile
Common Side Effects
- Mild gastrointestinal upset
- Headache
- Changes in appetite
- Fatigue or transient energy changes during initial dosing
Rare or Theoretical
- Disturbances in methylation balance with prolonged use
- Theoretical effects on mood or cognition via altered SAM/methylation
- Unknown long-term effects on tissues that normally express NNMT
Contraindications
- Pregnancy and breastfeeding
- Active or recent cancer without oncology supervision
- Significant liver or kidney impairment
- Adolescents and individuals under 18
- Known hypersensitivity to the compound
Drug Interactions
- Other NAD+ modulators (NMN, NR, niacin) — additive effects on NAD+ pathways
- Methyl donor supplements (SAMe, methylated B vitamins) — possible compounded effects on methylation
- Diabetes and weight-loss medications — theoretical additive metabolic effects
- Chemotherapy agents — NNMT is implicated in tumor biology; coordinate with oncology
Monitoring: Users working with a clinician may track body composition, fasting glucose and insulin, lipid panel, and general methylation-related labs (homocysteine, B12, folate) over longer cycles. Discontinue and seek medical advice for unexpected symptoms.
Who This Is For
- Metabolically healthy adults exploring research-stage tools for body composition under clinician guidance.
- Longevity-focused individuals interested in NAD+ and methylation biology.
- Adults who have plateaued on diet, training, and foundational supplementation and are evaluating advanced options.
- Researchers and clinicians studying NNMT as a metabolic target.
Who Should Avoid This
- Anyone pregnant, breastfeeding, or trying to conceive.
- Individuals with active cancer, significant organ impairment, or complex medication regimens without specialist oversight.
- People seeking an FDA-approved weight-loss medication — 5-Amino-1MQ is investigational.
- Adolescents and anyone under 18.
Frequently Asked Questions
What is 5-Amino-1MQ?
5-Amino-1MQ is a small-molecule selective inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme involved in cellular energy metabolism and methylation. It is studied primarily for metabolic and body-composition effects.
How does 5-Amino-1MQ work?
It blocks NNMT, which preserves nicotinamide (a NAD+ precursor) and S-adenosylmethionine (SAM) inside cells, particularly in fat and muscle tissue. This shifts cellular metabolism toward higher energy expenditure and improved methylation capacity.
Is 5-Amino-1MQ a peptide?
No. 5-Amino-1MQ is a small organic molecule (a methylquinolinium derivative), not a peptide. It is structurally and mechanistically very different from peptides like Semax, Selank, or BPC-157.
Does 5-Amino-1MQ help with fat loss?
Animal studies suggest reductions in fat mass and improved metabolic markers without changes in food intake, but human clinical evidence is limited. It should not be considered a proven weight-loss treatment.
Is 5-Amino-1MQ FDA-approved?
No. 5-Amino-1MQ is an investigational research compound and is not approved by the FDA for any indication, including weight loss or metabolic disease.
Is 5-Amino-1MQ legal?
It is generally sold as a research chemical in the United States and is not a controlled substance, but it is not approved for human therapeutic use. Legal status and availability can vary by jurisdiction and supplier.
How should 5-Amino-1MQ be taken?
It is most commonly used orally, once daily, often in cycles. Because it is investigational and human dosing is not standardized, any use should be guided by a qualified clinician.
How long does it take to work?
5-Amino-1MQ does not produce acute felt effects. Mechanistic and body-composition changes in research models develop over weeks of consistent dosing rather than hours or days.
Can 5-Amino-1MQ be stacked with NAD+ or NMN?
Conceptually they target overlapping biology — NAD+ availability — and are sometimes discussed together. However, combining novel compounds increases unknowns, so stacking should be done thoughtfully and ideally under medical supervision.
What are the main side effects of 5-Amino-1MQ?
Reported tolerability is generally mild, with possible GI upset, headache, or changes in appetite and energy. Long-term safety in humans has not been established.
Does DrSeinfeld sell 5-Amino-1MQ?
No. DrSeinfeld does not currently carry 5-Amino-1MQ. For NAD+ and metabolic support, we offer Cellular Vitality Nasal Spray (NAD+), SLU-PP-332, MitoShred, and other doctor-formulated options.
What's a good alternative to 5-Amino-1MQ for energy and metabolism?
Depending on goals, doctor-formulated alternatives include intranasal NAD+ for cellular energy, SLU-PP-332 for mitochondrial and exercise-mimetic support, and MitoShred for layered metabolic support — all available through DrSeinfeld.
